Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alkermes
Pharma
Even through its remake, Alkermes retains upward trajectory: CEO
Alkermes is showcasing its rare set of attributes as a pure-play neuroscience biotech that is self-funded and has an intriguing pipeline program.
Kevin Dunleavy
Jan 13, 2025 7:36am
Alkermes reports strong trajectory for Lybalvi, shares up 10%
Feb 15, 2024 1:10pm
JPM24, Day 3: CRISPR, BioMarin, Alkermes and more
Jan 10, 2024 7:00pm
JPM24: Alkermes ready to roll as pure-play neuroscience company
Jan 10, 2024 9:04am
Novo puts down $92.5M for Alkermes' Ireland plant, staffers
Dec 14, 2023 10:57am
Alkermes grants Teva license to launch generic Vivitrol in 2027
Aug 31, 2023 10:05am
